Evaluation of Rare Variants in the New Fanconi Anemia Gene<i>ERCC4</i>(<i>FANCQ</i>) as Familial Breast/Ovarian Cancer Susceptibility Alleles

Ana Osório, Massimo Bogliolo, María Victoria Fernández, Alicia Barroso, Miguel de la Hoya, Adriana Lasa, Teresa Ramón y Cajal, Marta Santamariña, Ana Vega, Francisco Quiles,

Human Mutation · 2013 · 30 citations · 13 references

DOIFull text

Open access

Concepts

Abstract

Recently, it has been reported that biallelic mutations in the ERCC4 (FANCQ) gene cause Fanconi anemia (FA) subtype FA-Q. To investigate the possible role of ERCC4 in breast and ovarian cancer susceptibility, as occurs with other FA genes, we screened the 11 coding exons and exon-intron boundaries of ERCC4 in 1573 index cases from high-risk Spanish familial breast and ovarian cancer pedigrees that had been tested negative for BRCA1 and BRCA2 mutations and 854 controls. The frequency of ERCC4 mutation carriers does not differ between cases and controls, suggesting that ERCC4 is not a cancer susceptibility gene. Interestingly, the prevalence of ERCC4 mutation carriers (one in 288) is similar to that reported for FANCA, whereas there are approximately 100-fold more FA-A than FA-Q patients, indicating that most biallelic combinations of ERCC4 mutations are embryo lethal. Finally, we identified additional bone-fide FA ERCC4 mutations specifically disrupting interstrand cross-link repair.

References

13